Xeris Biopharma Holdings, Inc. Stock Nasdaq
Equities
XERS
US98422L1070
Pharmaceuticals
Sales 2024 * | 185M 252M | Sales 2025 * | 219M 300M | Capitalization | 261M 357M |
---|---|---|---|---|---|
Net income 2024 * | -60M -82.02M | Net income 2025 * | -30M -41.01M | EV / Sales 2024 * | 1.41 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.19 x |
P/E ratio 2024 * |
-4.17
x | P/E ratio 2025 * |
-8.38
x | Employees | 377 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.58% |
Latest transcript on Xeris Biopharma Holdings, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Paul Edick
CEO | Chief Executive Officer | 67 | 21-04-30 |
Steven Pieper
DFI | Director of Finance/CFO | 47 | 21-09-30 |
John Shannon
PSD | President | 62 | 21-10-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Johnson
BRD | Director/Board Member | 66 | 21-10-04 |
Jeffrey Sherman
BRD | Director/Board Member | 69 | 21-10-04 |
Marla Persky
BRD | Director/Board Member | 68 | 21-10-04 |
1st Jan change | Capi. | |
---|---|---|
+30.00% | 684B | |
+30.34% | 568B | |
-3.75% | 361B | |
+18.24% | 329B | |
+4.07% | 284B | |
+16.21% | 240B | |
+9.66% | 208B | |
-6.83% | 200B | |
+7.04% | 166B |